SCHEMBL4289357

SCHEMBL4289357

Cc1ccc(-n2c(C=CN(C)C)c([N+](=O)[O-])c3ccc(O)c(CN(C)C)c32)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.73
HTT P42858 5/20 0.73
ALDH1A1 P00352 4/20 0.73
LMNA P02545 3/20 0.60
GAA P10253 3/20 0.50
KDM4E B2RXH2 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
PKM P14618 1/20 0.48
NPSR1 Q6W5P4 2/20 0.41
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MMP14 P50281 2/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
CLK1 P49759 1/20 0.31
GSK3B P49841 1/20 0.31
DYRK1A Q13627 1/20 0.31
CLK4 Q9HAZ1 1/20 0.31
DYRK1B Q9Y463 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289356 1.00 MAPT (0.73) MAPTHTTALDH1A1LMNAGAA
SCHEMBL4288409 0.90 ALDH1A1 (0.73) MAPTHTTALDH1A1LMNAGAA
SCHEMBL4288413 0.90 ALDH1A1 (0.73) MAPTHTTALDH1A1LMNAGAA
SCHEMBL4281505 0.84 ALDH1A1 (1.00) MAPTHTTALDH1A1LMNAGAA
SCHEMBL4239438 0.82 MAPT (0.49) MAPTHTTALDH1A1LMNAGAA
SCHEMBL4246818 0.77 ALDH1A1 (0.56) MAPTHTTALDH1A1LMNAGAA
SCHEMBL4060137 0.76 MAPT (0.82) MAPTHTTALDH1A1LMNAGAA
SCHEMBL4286778 0.76 ALDH1A1 (0.83) MAPTHTTALDH1A1LMNAGAA
SCHEMBL4289249 0.76 MAPT (0.71) MAPTHTTALDH1A1LMNAGAA
SCHEMBL4289246 0.76 MAPT (0.71) MAPTHTTALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883504-B2 Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line ASAHI KASEI KABUSHIKI KAISHA (JP) 2014-11-11 US disclosed
US-20090155906-A1 CELL DIFFERENTIATION SUPPRESSING AGENT, METHOD OF CULTURING CELLS USING THE SAME, CULTURE SOLUTION, AND CULTURED CELL LINE MIYABAYASHI TOMOYUKI 2009-06-18 US disclosed
EP-1640449-A1 CELL DIFFERENTIATION INHIBITING AGENT, CELL CULTURE METHOD USING THE SAME, CULTURE MEDIUM AND CULTURED CELL LINE Asahi Kasei Kabushiki Kaisha (JP) 2006-03-29 EP disclosed
US-20050153941-A1 Increasing Stage Specific Embryonic Antigen (SSEA) and Nanog gene levels; culturing a stem cell using a low molecular weight derivative of 2-(phenylazo)-2-(3,4-dihydro-2H-isoquinoline-1-ylidene) or N-phenylindole ASAHI KASEI KABUSHIKI KAISHA (JP) 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153941-A1 Increasing Stage Specific Embryonic Antigen (SSEA) and Nanog gene levels; culturing a stem cell using a low molecular weight derivative of 2-(phenylazo)-2-(3,4-dihydro-2H-isoquinoline-1-ylidene) or N-phenylindole MKI67, ALPG, NES MAPT 4659/4885HTT 4510/4885ALDH1A1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.